The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
FDA Drug Approval Summary: Pegaspargase (Oncaspar®) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL)
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe the effect of pegylation on asparaginase pharmacokinetics and immunogenicity.Identify the current pegaspargase indications.Discuss the advantages of pegaspargase treatment.Outline the clinical trial design leading to pegaspargase approval by the FDA.List the major adverse events associated with pegaspargase treatment. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Avramis, V. I., Sencer, S., Periclou, A. P., Sather, H., Bostrom, B. C., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Franklin, J., Gaynon, P. S., et al. (2002) · Blood · doi:10.1182/blood.v99.6.1986 · Cited by 492
BROOME, J. D. (1961) · Nature · doi:10.1038/1911114a0 · Cited by 459
Clavell, L. A., Gelber, R. D., Cohen, H. J., Hitchcock-Bryan, S., Cassady, J. R., Tarbell, N. J., Blattner, S. R., Tantravahi, R., Leavitt, P., & Sallan, S. E. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151101 · Cited by 416
Pui, C.-H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322407 · Cited by 379
Avramis, V. I., & Panosyan, E. H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544040-00003 · Cited by 240
Boos, J., Werber, G., Ahlke, E., Schulze-Westhoff, P., Nowak-Göttl, U., Würthwein, G., Verspohl, E. J., Ritter, J., & Jürgens, H. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00131-1 · Cited by 218
E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children
Tallal, L., Tan, C., Oettgen, H., Wollner, N., McCarthy, M., Helson, L., Burchenal, J., Karnofsky, D., & Murphy, M. L. (1970) · Cancer · doi:10.1002/1097-0142(197002)25:2<306::aid-cncr2820250206>3.0.co;2-h · Cited by 174
Riccardi, R., Holcenberg, J. S., Glaubiger, D. L., Wood, J. H., & Poplack, D. G. (1981) · PubMed · Cited by 167
Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P., & Buchanan, G. R. (2000) · Blood · doi:10.1182/blood.v96.5.1709 · Cited by 152
Pegylation: Engineering Improved Biopharmaceuticals for Oncology
Molineux, G. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.9.3s.32886 · Cited by 142
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond
Ganapathy, V., Thangaraju, M., & Prasad, P. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.005 · Cited by 710
Metadata
- Authors
- Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., & Pazdur, R.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-08-01
- Volume
- 12
- Issue
- 8
- Pages
- 991-998
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2164520862
- Cited by
- 324
- References
- 13
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Drug Approval Summary: Pegaspargase (Oncaspar®) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL). https://app.cochat.ai/papers/10.1634/theoncologist.12-8-991
- The paper
- Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2007). FDA Drug Approval Summary: Pegaspargase (Oncaspar®) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL). The Oncologist. https://doi.org/10.1634/theoncologist.12-8-991
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.